Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16745292 | 1.00 | DRD2 (0.32) | DRD2TOP1DRD1HTR3ASLC6A4 | |
| SCHEMBL16814045 | 1.00 | DRD2 (0.32) | DRD2TOP1DRD1HTR3ASLC6A4 | |
| SCHEMBL17070587 | 0.96 | TOP1 (0.38) | DRD2TOP1KMT2A | |
| SCHEMBL16812582 | 0.96 | TOP1 (0.38) | DRD2TOP1KMT2A | |
| SCHEMBL17070567 | 0.96 | TOP1 (0.38) | DRD2TOP1KMT2A | |
| SCHEMBL16748896 | 0.87 | DRD1 (0.33) | DRD1 | |
| SCHEMBL16813907 | 0.87 | DRD1 (0.33) | DRD1 | |
| SCHEMBL16745246 | 0.87 | DRD1 (0.33) | DRD1 | |
| SCHEMBL16812580 | 0.87 | DRD1 (0.33) | DRD1 | |
| SCHEMBL16745328 | 0.85 | DRD1 (0.40) | DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9518014-B2 | Process for synthesis of ezetimibe and intermediates used in said process | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2016-12-13 | — | — | US | disclosed |
| EP-2876102-B1 | PROCESS FOR SYNTHESIS OF EZETIMIBE AND INTERMEDIATES USED IN SAID PROCESS | SHANGHAI INST ORGANIC CHEMISTRY CAS (CN) | 2016-12-07 | — | — | EP | disclosed |
| US-20150166479-A1 | PROCESS FOR SYNTHESIS OF EZETIMIBE AND INTERMEDIATES USED IN SAID PROCESS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2015-06-18 | — | — | US | disclosed |
| EP-2876102-A1 | PROCESS FOR SYNTHESIS OF EZETIMIBE AND INTERMEDIATES USED IN SAID PROCESS | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2015-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166479-A1 | PROCESS FOR SYNTHESIS OF EZETIMIBE AND INTERMEDIATES USED IN SAID PROCESS | HMGCR, COASY, APOB | DRD2 4462/4885TOP1 1360/4885DRD1 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.